The global market for artificial intelligence in pharmaceuticals is on track to hit $28.63 billion by 2034, driven by a rapid push to use AI across the entire drug discovery process. Algorithms can now identify drug targets, analyze protein structures, and simulate chemical interactions at a speed and scale conventional lab methods cannot match, according to a new report from Polaris Market Research.
The economics behind this shift are stark. Bringing a single drug through clinical trials and FDA approval can cost between $161 million and $2 billion, and only a small fraction of drug candidates that enter trials ultimately succeed. That high cost to success ratio is pushing the industry toward AI driven approaches aimed at improving success rates and lowering expenses. By technology, natural language processing led the market with a 35.64 percent revenue share in 2025, valued for translating complex clinical and biological data into forms usable by medical experts and patients. Machine learning, deep learning, and generative AI tools are also gaining ground, with generative AI increasingly used to design new molecular structures and predict therapeutic potential.
AI is also reshaping clinical trials. It improves patient recruitment through electronic health record and genomic data mining, while predictive analytics help flag risk and refine dosing in real time. One of the largest opportunities lies in rare and high burden diseases that have historically been underinvested in due to poor return on development costs. Alzheimer's disease illustrates the scale of the challenge. More than 7 million Americans currently live with the disease, and unpaid caregiving in 2024 totaled nearly 19.2 billion hours, valued at over $413 billion. Without breakthroughs, the affected population could reach 13.8 million by 2050, with costs approaching $1 trillion.
Regional Growth and Remaining Hurdles
Regionally, North America led with a 49.80 percent revenue share in 2025, while Asia Pacific is set to post the fastest growth, driven by government backed AI adoption initiatives in China, India, and South Korea. On deployment, cloud based services captured the largest market share in 2025, favored particularly by startups and smaller firms that want to avoid heavy upfront infrastructure costs.
Barriers remain, including a shortage of skilled personnel, high implementation costs, and limited acceptance among some healthcare providers. Yet the trajectory is clear. As AI tools become more embedded in drug development, the hope is that more treatments for devastating diseases will reach patients faster and at lower cost, turning today’s data into tomorrow’s therapies.